Consistent with our hypothesis, treatment of the H358 human lung cancer cell line or the Lewis lung carcinoma (LLC) (heterozygous for KrasG12C) mouse lung cancer cell line with the FDA-approved KRASG12C inhibitor AMG 510 (28) attenuated KRAS activity and p-STAT3 and CD47 expression, enhanced miR-34a expression, and stimulated macrophage-mediated phagocytosis in both H358 and LLC cells (Figure 8, A–F, and Supplemental Figure 14, A–C). Here, KRAS is linked to lung carcinoma.